68120-35-4

Usage

Uses

Used in Pharmaceutical Industry:
(3-Bromo-4-Methylphenyl)Methanol is used as an intermediate in the synthesis of various pharmaceuticals for its unique chemical properties that facilitate the creation of diverse medicinal compounds.
Used in Organic Compounds Synthesis:
BM-4-MP is utilized as a key intermediate in the production of a range of organic compounds, leveraging its distinctive structure to form complex molecules for various applications.
Used in Fragrance and Flavor Industry:
(3-Bromo-4-Methylphenyl)Methanol is employed as a component in the development of fragrances and flavors, capitalizing on its chemical composition to contribute distinct scents and tastes in consumer products.
Used in Chemical Research:
BM-4-MP serves as a valuable compound in scientific research, where its unique properties are explored for potential applications in new chemical reactions and processes.

Upstream product

• 7697-26-9 3-bromo-4-methylbenzoic acid 
• 104-87-0 4-methyl-benzaldehyde 
• 36276-24-1 3-bromo-4-methyl-benzaldehyde 

Downstream Products

• 72985-21-8 5-(hydroxymethyl)-2-methylbenzoic acid 
• 1260824-22-3 1,3-bis(3-bromo-4-methylphenyl)urea 
• 183723-09-3 3-bromo-4-methyl-benzamide 
• 1544739-91-4 (3-(2-methoxypyridin-4-yl)-4-methylphenyl)methanol 
• 1544739-92-5 4-(5-(bromomethyl)-2-methylphenyl)-2-methoxypyridine 
• 1544739-93-6 (5aR,6S,6aS)-ethyl 3-((3-(2-methoxypyridin-4-yl)-4-methylbenzyl)oxy)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-c]pyridine-6-carboxylate 
• 1544739-90-3 (5aR,6S,6aS)-3-((3-(2-methoxypyridin-4-yl)-4-methylbenzyl)oxy)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-c]pyridine-6-carboxylic acid 
• 1400755-04-5 [4-methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-methanol 
• 72985-24-1 methyl 5-(hydroxymethyl )-2-methylbenzoate 
• 675148-96-6 methyl 5-formyl-2-methylbenzoate 
• 105650-34-8 5-formyl-2-methylbenzoic acid 
• 315188-34-2 5-(hydroxymethyl)-2-methylbenzonitrile 
• 1609540-80-8 (3-bromo-4-methylbenzyloxy)(tert-butyl)dimethylsilane 
• 1609540-87-5 tert-butyldimethyl((4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)silane 

Relevant academic research and scientific papers

ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS

The present invention relates to a compound represented by formula I: and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Synthesis of benzyl alcohol building blocks bearing an aldehyde, pinacol borane or carboxylic acid motif via lithium-bromide exchange

A range of useful disubstituted benzyl alcohol building blocks have been synthesised in multigram quantities in a lithium-bromide exchange to give aldehyde, carboxylic acid and pinacol -boranes in high yields. Georg Thieme Verlag Stuttgart · New York.

ANTIDIABETIC TRICYCLIC COMPOUNDS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

ANTIDIABETIC TRICYCLIC COMPOUNDS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY

The present invention relates to compounds of formula (I), which have valuable pharmacological properties, in particular are activators of AMPK and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

OLEFIN SUBSTITUTED OXINDOLES HAVING AMPK ACTIVITY

The present invention relates to compounds of formula (I), which have valuable pharmacological properties, in particular are activators of AMPK and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

Modeling, synthesis, and biological evaluation of potential retinoid X receptor (RXR) selective agonists: Novel analogues of 4-[1-(3,5,5,8,8- Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and (E)-3-(3-(1,2,3,4-tetrahydro-1,1,

Three unreported analogues of 4-[1-(3,5,5,8,8-pentamethyl-5-6-7-8- tetrahydro-2-naphthyl)ethynyl]benzoic acid (1), otherwise known as bexarotene, as well as four novel analogues of (E)-3-(3-(1,2,3,4-tetrahydro-1,1,4,4,6- pentamethylnaphthalen-7-yl)-4-hydr

THERAPEUTIC COMPOUNDS

The invention provides compounds of formulae (I), (II), (III), and (IV): and salts thereof, as well as pharmaceutical compositions comprising such compounds. The compounds are useful for treating cancers and Alzheimer's disease.

PYRIMIDINE COMPOUNDS AND METHODS OF USE

The invention provides pyrimidine compounds having formula (A): The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Src kinase family, and various other specific receptor and non-receptor kinases.